The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4

Kyung Hee Han,1,2 Noh Hyun Park,2 Jin Ju Kim,2 Sunmie Kim,3 Hee Seung Kim,2 Maria Lee,2 Yong Sang Song2,4

1Department of Obstetrics and Gynecology, Inha University Hospital, Incheon, Korea
2Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
3Department of Obstetrics and Gynecology, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea
4Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

ABSTRACT

Objective: To identify the power of tumor markers for predicting ovarian cancer according to menopausal status.

Methods: The medical records of 876 women with ovarian cysts were retrospectively reviewed. Cancer antigen 125 (CA 125), human epididymis protein 4 (HE4), and Risk of Ovarian Malignancy Algorithm (ROMA) were analyzed. Sensitivity, specificity, and the receiver operating characteristic (ROC) curve analyses of these tumor markers were evaluated.

Results: The sensitivity of ROMA was 66.7% and the specificity was 86.8% to detect ovarian malignancy. The patients were divided into 2 groups according to menopausal status: premenopause (n=532, 60.7%) and postmenopause (n=344, 39.3%). For diagnostic accuracy, ROMA was lower than HE4 in premenopausal women (82.7% vs. 91.4%) and lower than CA 125 in postmenopausal women (86.9% vs. 88.7%). The ROC curve analysis revealed that the power of ROMA was not significantly better than that of HE4 in premenopausal women (AUC, 0.731 vs. 0.732, p=0.832), and it was also not significantly better than that of CA 125 in postmenopausal women (AUC, 0.871 vs. 0.888, p=0.440).

Conclusion: The discrimination power of tumor markers for ovarian cancer was different according to menopausal status. In predicting ovarian malignancy, ROMA was neither superior to HE4 in premenopausal women nor superior to CA 125 in postmenopausal women.

Keywords: Tumor Markers; CA 125 Antigen; HE4 Protein, Human; Ovarian Epithelial Cancer; Menopause

INTRODUCTION

Ovarian cancer is the fifth most common female cancer worldwide and its mortality rate is 20%. Because women with early stages of ovarian cancer have few definite clinical symptoms, over 80% of ovarian cancer is diagnosed in the advanced stages [1]. To overcome the high mortality of ovarian cancer, multiple studies focusing on screening for ovarian cancer have been performed worldwide.
The power of tumor markers by menopausal status

To detect ovarian cancer, tumor markers are usually measured along with transvaginal ultrasound examination (TVU). A traditional tumor marker for ovarian cancer is cancer antigen 125 (CA 125), a high molecular weight glycoprotein which reacts to the monoclonal antibody generated from ovarian cancer cell line. CA 125 was elevated in some kinds of cancers including ovary. Finally, it had been the most commonly used biomarker for ovarian cancer [2]. However, CA 125 has clinical limitations as an effective tumor marker because it showed low specificity to predict ovarian cancer. Elevation of serum CA 125 is associated with benign conditions or physiological status as well as ovarian malignancy: endometriosis, uterine fibroids, pelvic inflammatory disease, menstruation, pregnancy, peritoneal tuberculosis, peritonitis, or following recent abdominal surgery [3]. Furthermore, CA 125 has low sensitivity especially in the early stage of ovarian cancer [4].

Human epididymis protein 4 (HE4) is translated from the WFDC2 gene. Although it was already known as an epididymis-specific protein, it was amplified in sera of patients with epithelial ovarian cancer [5]. Because HE4 showed higher specificity than CA 125, it has been identified as a tumor marker for ovarian cancer [6]. Even in endometriosis, HE4 was less affected than CA 125 [7,8]. When HE4 was used together with CA 125 to detect ovarian cancer, sensitivity and specificity were enhanced [9]. Thus, Risk of Ovarian Malignancy Algorithm (ROMA), the calculation with CA 125 and HE4 according to menopausal status, was proposed to discriminate ovarian cancer from benign conditions [10]. Many studies validated the discrimination power of ROMA including Asian populations [11].

However, some researchers could not identify the superiority of ROMA over CA 125 or HE4 alone and have tried to devise new potential tumor marker for ovarian cancer [12]. There were few studies that evaluated the effect of menopause on ROMA, although ROMA was induced from two different calculations according to menopausal status [10]. In Korea, ROMA is commonly used to detect ovarian malignancy without definite guidelines for general population [13]. Therefore, we designed this study to evaluate the discrimination power of ROMA compared with CA 125 or HE4 in Korean women.

MATERIALS AND METHODS

1. Patients
The Institutional Review Board of Seoul National University Hospital approved this study (IRB No. 1604-050-753). We retrospectively collected medical data of women who visited the hospital for regular checkup between March 2015 and March 2016 in Seoul National University Hospital and Seoul National University Hospital Healthcare System Gangnam Center, a medical college-based hospital and its health promotion and screening center. We defined that regular checkup is gynecologic examination with cervical cancer screening and TVU to physically healthy women without symptoms. Women with ovarian cystic masses of age 19 or higher, who underwent TVU and blood tests for CA 125, HE4, and ROMA were included in our study. Women who had previous history of gynecologic cancer were excluded, while survivors of non-gynecologic cancer were included.

2. Measurement
Blood tests for tumor markers of ovarian cancer were performed except during menstruation, and samples were examined within 4 hours of collection. The CA 125 and HE4 were measured using the ARCHITECT system (Abbott Diagnostics, Abbott Park, IL, USA). The calculation
of ROMA was performed as described by Moore et al. [10]. In postmenopausal women, the predictive index (PI)=−8.09+1.04×LN (HE4)+0.732×LN (CA 125). In premenopausal women, PI=−12.0+2.38×LN (HE4)+0.0626×LN (CA 125). The predictive probability (%)=exp (PI)/[1+exp (PI)]. The predictive probability corresponds to ROMA according to menopause status. Menopause was defined when a period of amenorrhea persisted over 1 year. If women had an unknown menstruation date, premenopause was determined by confirming serum follicle stimulating hormone level below 22 IU/L. The cut-off value for CA 125 was 35 IU/L. The instructions of our equipment applied different cut-off values for HE4: 70 IU/L in premenopausal women, and 140 IU/L in postmenopausal women [14].

TVU was performed to identify ovarian cyst or to find the morphologic abnormality of these lesions. Some patients underwent surgical exploration afterwards in case of the following surgical indications: findings suggesting malignancy, such as, solid portion, papillary projection, multiple septa, large volume, and increased color Doppler flow; symptoms related to ovarian cysts, such as abdominal pain, vaginal spotting, and mass effect [15,16]. Pathologic diagnosis was confirmed with specimen examination after surgical operation. Others were followed-up using TVU every 3 months to identify malignant transformation [17,18]. The number of patients newly diagnosed with ovarian malignancy within a year were investigated.

Two types of ovarian cancer, primary ovarian cancer including borderline ovarian malignancy and metastatic ovarian cancer originating from other organs, were analyzed in this study. Metastatic ovarian cancer was included when detected during preoperative work-up or when identified by pathologic diagnosis after surgical exploration.

3. Statistical analysis
Continuous or numeric variables, such as age and levels of tumor markers, were analyzed with the Student’s t-test or Mann-Whitney rank test. Nominal or ordinal variables, such as menopausal status and pathologic diagnosis were analyzed with χ² test or Fisher’s exact test. Receiver operating characteristic (ROC) curve analysis was performed to predict the risk of ovarian malignancy. To compare the area under the curve (AUC) between ROC curves, pairwise comparison analyses were used [19]. Statistical analyses were performed with SPSS 21 software (SPSS, Inc., Chicago, IL, USA). A p-value less than 0.05 was considered statistically significant.

RESULTS

Fig. 1 is the flow chart of this study for patients’ selection. A total of 876 women who had ovarian cysts on TVU underwent blood tests for tumor markers, including CA 125, HE4, and ROMA. Among them, 532 patients were premenopausal (60.7%) and 344 were postmenopausal women (39.3%). Surgical exploration and pathological diagnosis for ovarian cysts were conducted in 157 premenopausal women (29.5%) and 102 postmenopausal women (29.7%). In premenopausal women who took surgical exploration, there were 32 patients with primary ovarian cancer, 1 patient with secondary ovarian cancer, 11 patients with borderline ovarian malignancy, and 113 patients with benign ovarian cysts. In postmenopausal women who took surgical exploration, there were 48 patients with primary ovarian cancer, 2 patients with secondary ovarian cancer, 1 patient with borderline ovarian malignancy, and 51 patients with benign ovarian cysts. The other women took serial monitoring with TVU. Among them, there were 375 women with premenopause (70.5%) and 242 women with postmenopause (70.4%).
Table 1 shows the patients' characteristics according to menopausal status. Distribution of elevated CA 125 and ovarian lesions between pre- and postmenopausal women were analyzed with \( \chi^2 \) tests. The values of CA 125, HE4, and ROMA did not follow normal distribution and were skewed to the lower level within the reference range. The proportion of elevated CA 125 was higher in the premenopausal women than in the postmenopausal women (\( p=0.003 \)), whereas the proportion of elevated HE4 and high-risk ROMA was higher in the postmenopausal group than in the premenopausal group (\( p=0.001 \) and \( p=0.036 \)).

Most of the ovarian cystic masses primarily found on TVU had benign nature. Malignant lesions were more frequently found in postmenopausal women than in premenopausal women (\( p<0.001 \)). The number of patients with primary ovarian cancer in the premenopausal group was 32 (6.0%) and that in the postmenopausal group was 48 (14.0%). A total of 13 patients had ovarian metastasis from other organs. The origins of metastatic tumor to the ovary were the uterine endometrium (n=5, 38.5%), intestine (n=3, 23.1%), stomach (n=2, 15.4%), pancreas (n=1, 7.7%), and bile duct (n=2, 15.4%). The number of uterine endometrial cancer was 1 (0.2%) in premenopausal and 4 (1.2%) in postmenopausal women.

Among the patients, 123 women (14.0%) had previous history of non-gynecologic malignancy: breast (n=75, 8.6%), stomach and colorectal (n=21, 2.4%), and hepatobiliary cancer (n=9, 1.0%). In patients with previous breast cancer, 1 woman had \textit{BRCA1} mutation and 1 woman had \textit{BRCA2} mutation (2.6%). The type of underlying malignancy did not correlate with the existence of malignant ovarian cyst (\( p=0.294 \)). There was no difference

### Table 1. Patients' characteristics according to menopause status

| Characteristics                  | Premenopause (n=532, 60.7%) | Postmenopause (n=344, 39.3%) | \( p \) |
|----------------------------------|-----------------------------|------------------------------|-------|
| Age (yr)                         | 42 (20–60)                  | 58 (40–82)                   | <0.001|
| Increased tumor markers          |                             |                              |       |
| CA 125                           | 153 (28.8)                  | 68 (19.8)                    | 0.003 |
| HE4                              | 26 (4.9)                    | 37 (10.8)                    | 0.001 |
| ROMA                             | 92 (17.3)                   | 80 (23.3)                    | 0.036 |
| Ovarian mass                     |                             |                              | <0.001|
| Primary ovarian cancer           | 32 (6.0)                    | 48 (14.0)                    |       |
| Metastasis to ovary              | 3 (0.6)                     | 10 (2.9)                     |       |
| Ovarian borderline malignancy    | 11 (2.1)                    | 1 (0.3)                      |       |
| Benign ovarian cyst              | 486 (91.4)                  | 285 (82.6)                   |       |

Values are presented as median (range) or number (%).
CA 125, cancer antigen 125; HE4, human epididymis protein 4; ROMA, Risk of Ovarian Malignancy Algorithm.
in the three tumor markers between primary and metastatic ovarian cancer: serum CA 125 levels, serum HE4 levels, and ROMA value (p=0.074, p=0.349, p=0.713, respectively).

Table 2 shows the histopathologic results of primary ovarian cancer which were evaluated in this study. The postmenopausal group had significantly more patients with an advanced stage (p=0.016) and a higher pathologic grade (p=0.003) than the premenopausal group. Among the various histological types, serous cystadenocarcinoma was most common in both premenopausal and postmenopausal groups.

Table 3 indicates the predictive power of tumor markers for ovarian cancer. The overall sensitivity of ROMA to discriminate ovarian malignancy was 66.7% and the overall specificity was 86.8%. HE4 had the highest positive predictive value and ROMA had the highest negative predictive value to detect ovarian malignancy among CA 125, HE4, and ROMA. These tumor markers had distinct diagnostic accuracy depending on menopausal status. The diagnostic accuracy of HE4 was high in premenopausal women and that of CA 125 was high in postmenopausal women.

Fig. 2 shows the ROC curves of tumor markers according to menopausal status. In premenopausal women, AUCs of variables were 0.685 for CA 125 (95% confidence interval [CI]=0.644–0.725), 0.732 for HE4 (95% CI=0.692–0.769), and 0.731 for ROMA (95% CI=0.691–0.768). The difference between the AUCs of the ROC curves of HE4 and ROMA was not

**Table 2.** Histopathologic results of primary ovarian cancer

| Characteristics | Premenopause (n=32, 40%) | Postmenopause (n=48, 60%) | p    |
|----------------|--------------------------|---------------------------|------|
| FIGO stage     |                          |                           |      |
| I              | 17 (53.1)                | 10 (20.8)                 | 0.016|
| II             | 4 (12.5)                 | 6 (12.5)                  |      |
| III            | 7 (21.9)                 | 15 (31.3)                 |      |
| IV             | 4 (12.5)                 | 17 (35.4)                 |      |
| Grade          |                          |                           | 0.003|
| 1 (low)        | 14 (48.3)                | 7 (14.6)                  |      |
| 2, 3 (high)    | 15 (51.7)                | 41 (85.4)                 |      |
| Histology      |                          |                           | 0.172|
| Serous         | 12 (37.5)                | 27 (56.3)                 |      |
| Endometrioid   | 5 (15.6)                 | 8 (16.7)                  |      |
| Mucinous       | 5 (15.6)                 | 1 (2.1)                   |      |
| Clear cell     | 3 (9.4)                  | 4 (8.3)                   |      |
| Others         | 7 (21.9)                 | 8 (16.7)                  |      |

FigO, International Federation of Gynecology and Obstetrics.

**Table 3.** Sensitivity and specificity of tumor markers for ovarian cancer

| Characteristics | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Diagnostic accuracy (%) |
|----------------|----------------|-----------------|---------|---------|-------------------------|
| All women (n=876) |                |                  |         |         |                         |
| CA 125         | 65.7           | 80.3             | 31.2    | 94.5    | 78.5                    |
| HE4            | 35.2           | 96.6             | 58.7    | 91.6    | 89.3                    |
| ROMA           | 66.7           | 86.8             | 40.7    | 95.0    | 84.4                    |
| Premenopause (n=532) |            |                  |         |         |                         |
| CA 125         | 54.3           | 73.7             | 16.3    | 94.5    | 72.0                    |
| HE4            | 28.3           | 97.3             | 50.0    | 93.5    | 91.4                    |
| ROMA           | 50.0           | 85.8             | 25.0    | 94.8    | 82.7                    |
| Postmenopause (n=344) |            |                  |         |         |                         |
| CA 125         | 74.6           | 91.6             | 64.7    | 94.6    | 88.7                    |
| HE4            | 40.7           | 95.4             | 64.9    | 88.6    | 86.0                    |
| ROMA           | 79.7           | 88.4             | 58.8    | 95.5    | 86.9                    |

CA 125, cancer antigen 125; HE4, human epididymis protein 4; NPV, negative predictive value; PPV, positive predictive value; ROMA, Risk of Ovarian Malignancy Algorithm.
statistically significant according to pairwise comparison analysis in premenopausal women (p=0.832, Fig. 2A). In postmenopausal women, the AUCs of variables were 0.888 for CA 125 (95% CI=0.849–0.919), 0.845 for HE4 (95% CI=0.803–0.882), and 0.871 for ROMA (95% CI=0.831–0.905). The difference between the AUCs of the ROC curves for CA 125 and ROMA was not statistically significant according to pairwise comparison analysis in postmenopausal women (p=0.440, Fig. 2B). Excluding secondary ovarian cancer, metastatic cancer from other organs to ovary, AUCs of tumor markers were as follows: 0.681 for CA 125 (95% CI=0.587–0.774), 0.734 for HE4 (95% CI=0.644–0.823), and 0.731 for ROMA (95% CI=0.639–0.822) in premenopausal women; 0.883 for CA 125 (95% CI=0.815–0.951), 0.837 for HE4 (95% CI=0.771–0.903), and 0.861 for ROMA (95% CI=0.789–0.932) in postmenopausal women.

**DISCUSSION**

In this study, we evaluated the power of ROMA to predict ovarian malignancy compared with CA 125 and HE4 alone according to the menopausal status of Korean women. Previous study on ROMA in Korean population suggested optimized weights of CA 125 and HE4 incorporated in ROMA [20]. Going one step forward from that previous study, we investigated the non-inferiority of existing tumor marker itself comparing ROMA according to menopausal status. There are some previous studies to propose the association between menopause and tumor markers for ovarian cancer. In our study, we included large number of women with ovarian cysts in Korean general population because we intended to evaluate the clinical usage and interpretation of common tumor markers for ovarian cancer according to menopause in general population. The results of our study correspond to previous studies which reported that menopausal status affected diagnostic ability of CA 125, HE4, or ROMA. Thus, clinicians would be helped to interpret ROMA by comparing CA 125 or HE4 according to menopausal status in actual clinical field [21,22].
In the same viewpoint, our study included patients with secondary ovarian cancer metastasis from other origin as well as primary ovarian cancer. TVU was usually conducted to women with ovarian cysts in the primary care, however, it had limitations in discriminating benign ovarian lesion, primary ovarian cancer, or secondary ovarian cancer. In this study, metastasis was confirmed after cancer workup or pathologic review after surgical exploration. The origins of secondary ovarian cancer were the uterine endometrium, colorectal, stomach, and biliary system in order of frequency. ROMA was increased in metastatic ovarian cancer from uterine endometrium or gastrointestinal tract [23].

We investigated the sensitivity, specificity, and ROC curves of ovarian tumor markers; CA 125, HE4, and ROMA. The highest sensitivity was found in ROMA and the highest specificity was found in HE4 without considering menopausal status. However, discrimination power of these tumor markers was different according to menopausal status [24]. As same as our results, previous studies reported that higher sensitivity and higher specificity of CA 125 were observed in postmenopausal women than in premenopausal women [25]. On the other hand, we analyzed that diagnostic accuracy of HE4 was higher in premenopausal women than in postmenopausal women. HE4 was more accurate in younger population, because HE4 levels increase according to age [26].

In the ROC curve analyses, menopausal status was associated with an effective tumor marker to identify ovarian malignancy including secondary ovarian cancer or not. Although the differences between the AUCs of the ROC curves were not significant, the widest areas were found under the ROC curve of CA 125 in postmenopausal women and under the ROC curve of HE4 in premenopausal women. A meta-analysis reported similar results to our study. CA 125 was more suitable than ROMA in postmenopausal women and HE4 was more suitable than ROMA in premenopausal women according to ROC curve analysis [27]. If menopausal status was checked in advance of the interpretation of tumor markers, HE4 or CA 125 alone was not inferior to ROMA in determining ovarian malignancy.

The discriminating power of ROMA for ovarian malignancy was not higher in our study than those found in previous studies. Unlike previous studies that included women with ovarian cysts who were scheduled to undergo surgery, our study included women with ovarian cysts found during regular check-up regardless of treatment thereafter [10]. Although there were few data on the predictability of ROMA for screening ovarian cancer, generalized ovarian cysts which we analyzed would have decreased the power of ROMA. Low HE4 would also have reduced the power of ROMA in our study. Most cases showed lower level of HE4 than the cut-off value by manufacturer’s guideline. HE4 level is known to be affected by ethnicity, and Asian populations had a wide reference range of HE4 [13,28]. In Korean women, a new cut-off level of HE4 was suggested to differentiate ovarian cancer from benign lesion. The revised cut-offs of HE4 in Korean was more predictable to ovarian cancer, and it was lower than the presented cut-offs by manufacturer’s guideline [29].

Our study has some limitations. The number of ovarian malignancy was not sufficient to establish a new cut-off level of HE4 in Korea women. However, we suggested the possibility of ROMA for ovarian cancer screening and assured the inadequate reference range of HE4 in Korean women. The whole women included in this study was not evaluated for BRCA mutation. However, the prevalence of BRCA mutation in included women with previous history of breast cancer was similar to the usual risk of BRCA mutation in Korean with breast cancer [30]. Despite
In conclusion, we investigated the discrimination power of ROMA compared with CA 125 or HE4 when considering menopausal status. ROMA was not superior to HE4 in premenopausal women and was not superior to CA 125 in postmenopausal women. Our study may help clinicians to clarify the clinical interpretation of ROMA. To apply ROMA for ovarian cancer screening to different ethnicities, an additional prospective study should be performed.

REFERENCES

1. Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer 2012;22 Suppl 1:S24-6. 
PUBMED | CROSSREF
2. Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 1986;46:6143-8. 
PUBMED
3. Montagnana M, Lippi G, Danese E, Franchi M, Guidi GC. Usefulness of serum HE4 in endometriotic cysts. Br J Cancer 2009;101:548. 
PUBMED | CROSSREF
4. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12. 
PUBMED | CROSSREF
5. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700. 
PUBMED
6. Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol 2013;8:11. 
PUBMED | CROSSREF
7. Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol 2013;128:233-8. 
PUBMED | CROSSREF
8. Shin JJ, Lee YJ, Kim R, Lee DH, Won KH, Lee BC. Analysis of falsely elevated risk of ovarian malignancy algorithm in women with ovarian endometrioma. Obstet Gynecol Sci 2016;59:295-302. 
PUBMED | CROSSREF
9. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8. 
PUBMED | CROSSREF
10. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6. 
PUBMED | CROSSREF
11. Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, et al. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. J Gynecol Oncol 2015;26:46-53. 
PUBMED | CROSSREF
12. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011;104:863-70. 
PUBMED | CROSSREF
13. Yu S, Lee JK, Kim JH, Park H, Lee MY, Ryu S, et al. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women. Gynecol Oncol 2016;143:128-34. 
PUBMED | CROSSREF
14. Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, et al. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the prediction of ovarian cancer in Korean women. J Korean Med Sci 2015;30:1777-83.

15. Glanc P, Benacerraf B, Boune T, Brown D, Coleman BG, Crum C, et al. First international consensus report on adnexal masses: management recommendations. J Ultrasound Med 2017;36:849-63.

16. Pavlik EI, Ueland FR, Miller RW, Ubellacker IM, DeSimone CR, Elder I, et al. Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstet Gynecol 2013;122:210-7.

17. Alcázar JL, Castillo G, Jurado M, García GL. Is expectant management of sonographically benign adnexal cysts an option in selected asymptomatic premenopausal women? Hum Reprod 2005;20:3231-4.

18. Greenlee RT, Kessel B, Williams CR, Riley TL, Ragard LR, Harget P, et al. Prevalence, incidence, and natural history of simple ovarian cysts among women >55 years old in a large cancer screening trial. Am J Obstet Gynecol 2010;202:373.e1-9.

19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.

20. Song HJ, Nam KM, Kim JD, Park CY, Kim YS. Looking for optimized weights of CA125 and HE4 in early screening system of ovarian cancer for Korean patients. Technol Health Care 2015;24 Suppl 1:S163-70.

21. Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer 2019;43:135-44.

22. Terlikowska KM, Dobrzycka B, Witkowska AM, Mackowiak-Matejczyk B, Sledziewski TK, Kinalski M, et al. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. J Ovarian Res 2016;9:43.

23. Van Gorp T, Veldman J, Van Calster B, Cadron I, Leunen K, Amant F, et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer 2012;48:1649-56.

24. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6.

25. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72:659-64.

26. Moore RG, Miller MC, Ekland EE, Lu KH, Bast RC Jr, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012;206:349.e1-7.

27. Dayan F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, et al. Diagnostic performance of Risk of Ovarian Malignancy Algorithm against CA125 and HE4 in connection with ovarian cancer: a meta-analysis. Int J Gynecol Cancer 2016;26:e1586-93.

28. Tian Y, Wang C, Cheng L, Zhang A, Liu W, Guo L, et al. Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women. J Ovarian Res 2015;8:72.

29. Park Y, Kim Y, Lee EY, Lee IH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer 2012;130:1136-44.

30. Ahn SH, Hwang UK, Kwak BS, Yoon HS, Ku BK, Kang HI, et al. Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Korean Med Sci 2004;19:269-74.